Natera Inc at JPMorgan Healthcare Conference Transcript
All right. Good morning. I'm Julia Qin, lead analyst covering life science tools and diagnostics at JPMorgan, and it's my great pleasure to introduce you to our next company presentation by Natera. And with that, let me turn it over to Steve.
Great. Thank you very much. So this is the standard safe harbor information. Many of you know Natera, but we are today the market leader in cell-free DNA technology. We launched our first test, Panorama, in 2013, which is a noninvasive prenatal test. We were the fourth company to market. And today, we believe we have more than 50% market share. In 2020, we expanded, use the same technology to move into the field of oncology and also into Organ Health. Looking across the portfolio, in women's health, we now have a full suite of services that we offer to physicians. Panorama noninvasive prenatal testing, Horizon screening and the Empower hereditary cancer testing. In oncology, we have our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
